MC 004
Alternative Names: MC-004Latest Information Update: 05 Jan 2026
At a glance
- Originator Medicovestor
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Endometriosis; Malignant-mesothelioma
Most Recent Events
- 11 Dec 2025 Preclinical trials in Endometriosis in USA (Parenteral) prior to December 2025 (Medicovestor pipeline, December 2025)
- 11 Dec 2025 Preclinical trials in Malignant mesothelioma in USA (Parenteral) prior to December 2025 (Medicovestor pipeline, December 2025)